These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35908133)

  • 1. Regulatory safety evaluation of nanomedical products: key issues to refine.
    De Jong WH; Geertsma RE; Borchard G
    Drug Deliv Transl Res; 2022 Sep; 12(9):2042-2047. PubMed ID: 35908133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Market entry system considering the biosafety of nanomedical devices in China.
    Wen H; Yang Y; Geng X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Nov; 14(6):e1821. PubMed ID: 36416024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Safe-by-Design Strategy towards Safer Nanomaterials in Nanomedicines.
    Yan L; Zhao F; Wang J; Zu Y; Gu Z; Zhao Y
    Adv Mater; 2019 Nov; 31(45):e1805391. PubMed ID: 30701603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS.
    Zabeo A; Rosada F; Pizzol L; Caputo F; Borgos SE; Parot J; Geertsma RE; Pouw JJ; Vandebriel RJ; Moreno OI; Hristozov D
    Drug Deliv Transl Res; 2022 Sep; 12(9):2101-2113. PubMed ID: 35538190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory landscape of nanotechnology and nanoplastics from a global perspective.
    Allan J; Belz S; Hoeveler A; Hugas M; Okuda H; Patri A; Rauscher H; Silva P; Slikker W; Sokull-Kluettgen B; Tong W; Anklam E
    Regul Toxicol Pharmacol; 2021 Jun; 122():104885. PubMed ID: 33617940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which is Better for Nanomedicines: Nanocatalysts or Single-Atom Catalysts?
    Zhao M; Zhang N; Yang R; Chen D; Zhao Y
    Adv Healthc Mater; 2021 Apr; 10(8):e2001897. PubMed ID: 33326185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
    Urbán P; Liptrott NJ; Bremer S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues affecting nanomedicines on the way from the bench to the market.
    Longo JPF; Mussi S; Azevedo RB; Muehlmann LA
    J Mater Chem B; 2020 Dec; 8(47):10681-10685. PubMed ID: 33155000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review.
    Feng X; Shi Y; Zhang Y; Lei F; Ren R; Tang X
    Int J Nanomedicine; 2024; 19():1509-1538. PubMed ID: 38384321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines - Tiny particles and big challenges.
    Marques MRC; Choo Q; Ashtikar M; Rocha TC; Bremer-Hoffmann S; Wacker MG
    Adv Drug Deliv Rev; 2019; 151-152():23-43. PubMed ID: 31226397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.
    Halamoda-Kenzaoui B; Vandebriel RJ; Howarth A; Siccardi M; David CAW; Liptrott NJ; Santin M; Borgos SE; Bremer-Hoffmann S; Caputo F
    J Control Release; 2021 Aug; 336():192-206. PubMed ID: 34126169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Main trends of immune effects triggered by nanomedicines in preclinical studies.
    Halamoda-Kenzaoui B; Bremer-Hoffmann S
    Int J Nanomedicine; 2018; 13():5419-5431. PubMed ID: 30271138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.